WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹96 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr | ₹108 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹96 Cr |
Mar2023 | ₹11 Cr |
Mar2022 | ₹11 Cr |
Mar2021 | ₹84 Cr |
Mar2020 | ₹108 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹96 Cr | 787.48 | |
Mar2023 | ₹11 Cr | 2.34 | |
Mar2022 | ₹11 Cr | -87.49 | |
Mar2021 | ₹84 Cr | -21.63 | |
Mar2020 | ₹108 Cr | - |
Compare Total Non-Current Liabilities of peers of WANBURY
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
WANBURY | ₹921.7 Cr | 1.2% | 5.7% | 20.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹382,622.0 Cr | 2% | -2.3% | -12.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,536.0 Cr | -1.3% | -6.2% | 21.2% | Stock Analytics | |
CIPLA | ₹125,468.0 Cr | -2.2% | 3.6% | -4.5% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹121,162.0 Cr | -0% | -0.3% | 5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,874.0 Cr | -0.9% | 4.5% | -8.6% | Stock Analytics |
WANBURY Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
WANBURY | 1.2% |
5.7% |
20.9% |
SENSEX | 1.1% |
-0.4% |
-2.2% |
You may also like the below Video Courses